What is RefleXion?
Founded in 2009 and headquartered in Hayward, California, RefleXion operates at the intersection of oncology and advanced medical technology. The company specializes in biotargeting, a sophisticated approach to cancer treatment that integrates real-time biological data with precision radiation therapy. By focusing on the development of life-saving medical devices, RefleXion aims to improve patient outcomes through highly targeted interventions. Its market position is bolstered by a diverse portfolio of institutional backers who recognize the transformative potential of its technology in the global healthcare ecosystem.
How much funding has RefleXion raised?
RefleXion has raised a total of $587.6M across 8 funding rounds:
Series A
$11.6M
Series B
$6M
Series C
$100M
Unspecified
$60M
Private Equity
$100M
Private Equity
$80M
Debt
$125M
Other Financing Round
$105M
Series A (2014): $11.6M with participation from Sofinnova Partners and Venrock
Series B (2016): $6M led by Venrock, Sofinnova Partners, KCK, and Pfizer Venture Investments
Series C (2018): $100M supported by Sofinnova Partners, GT Healthcare Capital Partners, KCK, Venrock, Pfizer Venture Investments, and The Rise Fund
Unspecified (2019): $60M featuring Oxford Finance
Private Equity (2020): $100M backed by Public Sector Pension Investment Board
Private Equity (2022): $80M with participation from PSP Investments, KCK Group, The Rise Fund, and T. Rowe Price
Debt (2022): $125M led by Oxford Finance
Other Financing Round (2023): $105M supported by Johnson & Johnson, Squarepoint Capital, Pictet Asset Management, T. Rowe Price, TPG, Pfizer, The Rise Fund, and Ally Bridge Group
Key Investors in RefleXion
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability, known for its hands-on approach to building transformative companies.
Venrock
A historic venture capital firm based in Palo Alto, California, with a deep track record of supporting high-growth technology and healthcare ventures.
Pfizer
A global biopharmaceutical leader that researches and develops innovative medicines and vaccines, actively investing in oncology and therapeutic advancements.
What's next for RefleXion?
With the successful closure of its latest funding round, RefleXion is well-positioned to transition into a phase of accelerated commercialization and clinical expansion. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities, the expansion of clinical trial programs, and the enhancement of its core biotargeting software. As the company continues to mature, it remains focused on achieving long-term value creation by addressing critical unmet needs in oncology, ultimately aiming to set new benchmarks for efficacy and precision in radiation therapy on a global scale.
See full RefleXion company page
